bladder cancer

Treatment Advances, Predictive Biomarkers Stand to Improve Bladder Cancer Care

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to a New England Journal of Medicine editorial published by Matthew Milowsky, MD, FASCO, a bladder cancer expert at UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center.




bladder cancer

Treatment Advances, Predictive Biomarkers Stand to Improve Bladder Cancer Care

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to a New England Journal of Medicine editorial published by Matthew Milowsky, MD, FASCO, a bladder cancer expert at UNC School of Medicine and UNC Lineberger Comprehensive Cancer Center.




bladder cancer

Bladder cancer risk increasing in certain jobs: study

Sheffield, England – The risk of bladder cancer is rising in some occupations, a review of research from the University of Sheffield indicates.




bladder cancer

Good Hope leading the way internationally with bladder cancer laser treatment

A Good Hope consultant has won international recognition for leading a new treatment study




bladder cancer

What Are the 5 Warning Signs of Bladder Cancer?

Title: What Are the 5 Warning Signs of Bladder Cancer?
Category: Diseases and Conditions
Created: 4/22/2021 12:00:00 AM
Last Editorial Review: 6/8/2022 12:00:00 AM




bladder cancer

New drug cuts the risk of death in bladder cancer by 30% compared with chemotherapy, study suggests

A new type of drug that targets chemotherapy directly to cancer cells reduces the risk of death from the most common type of bladder cancer by 30%, a phase III trial in the New England Journal of Medicine has suggested.




bladder cancer

'I try not to think about myself': Woman battles breast cancer while caring for mum who has gall bladder cancer

To mark Breast Cancer Awareness Month, we speak to inspiring Singaporeans about their journey in battling and overcoming cancer.  Warda Ismail gets anxious about things easily, especially when it comes to her health.  So much so that her doctor once told her that she is a "borderline hypochondriac", she shared with AsiaOne in an interview.  For the uninitiated, hypochondria is a condition where a person is excessively and unduly worried about having a serious illness. To keep her mind at ease, the 44-year-old preschool educator has the habit of going for regular medical checkups.  Though she was vigilant, her worst nightmare came true — she was diagnosed with breast cancer on May 8 this year.  And in the midst of her recovery journey, she got more terrible news — her mother, who had been caring for her, was diagnosed with stage-three gall bladder cancer.  Despite the string of unfortunate events, Warda persevered and tried to have a more positive outlook on life and her health. 




bladder cancer

No Survival Gain from Extended Lymph Node Removal in Bladder Cancer

Extended lymph node removal during surgery for localized muscle-invasive medlinkbladder cancer/medlink does not improve patient survival(!--ref1--).




bladder cancer

The Y Chromosome Puzzle and Its Impact on Bladder Cancer Resistance

Recent research indicates that the progressive loss of Y chromosomes in aging men significantly impairs the body's capacity to combat bladder cancer.




bladder cancer

Tuning the phototherapeutic activity of Pt(IV) complexes for bladder cancer via modification of trans N-heterocyclic ligands

Inorg. Chem. Front., 2024, 11,7898-7909
DOI: 10.1039/D4QI01765J, Research Article
Open Access
  This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.
Huayun Shi, Guy J. Clarkson, Peter J. Sadler
The photochemotherapeutic activity of diazido Pt(IV) complexes towards bladder cancer, a common cancer with expensive treatment, has been tuned via modification of trans N-heterocyclic ligands, to give a candidate for preclinical development.
The content of this RSS Feed (c) The Royal Society of Chemistry




bladder cancer

Diabetes drug may raise bladder cancer risk: study

Compared with no thiazolidinedione use, pioglitazone associated with an overall 63 p.c. increased risk




bladder cancer

Immunotherapy after surgery helps people with high-risk bladder cancer live cancer-free longer

An NCI trial shows that giving patients pembrolizumab after surgery for high-risk muscle invasive bladder cancer doubles the median length of time that they remain cancer free, compared with observation alone after surgery.




bladder cancer

LifeBiotic's Botanical Formula Gives New Hope for Bladder Cancer Patients

Patented botanical formula LCS103 shows an 80% decrease in bladder cancer recurrence rate in a recent case series clinical trial




bladder cancer

Good Hope leading the way internationally with bladder cancer laser treatment

A Good Hope consultant has won international recognition for leading a new treatment study




bladder cancer

PET/CT imaging with a 18F-labeled galactodendritic unit in a galectin-1 overexpressing orthotopic bladder cancer model

Galectins are carbohydrate-binding proteins overexpressed in bladder cancer (BCa) cells. Dendritic galactose moieties have a high affinity for galectin-expressing tumor cells. We radiolabeled a dendritic galactose carbohydrate with fluorine-18 – 18F-labeled galactodendritic unit 4 – and examined its potential in imaging urothelial malignancies. Methods: The 18F-labeled 1st generation galactodendritic unit 4 was obtained from its tosylate precursor. We conducted in vivo studies in galectin-expressing UMUC3 orthotopic BCa model to determine the ability of 18F-labeled galactodendritic unit 4 to image BCa. Results: Intravesical administration of 18F-labeled galactodendritic unit 4 allowed specific accumulation of the carbohydrate radiotracer in galectin-1 overexpressing UMUC3 orthotopic tumors when imaged with PET. The 18F-labeled galactodendritic unit 4 was not found to accumulate in non-tumor murine bladders. Conclusion: The 18F-labeled galactodendritic unit 4 and similar analogs may be clinically relevant and exploitable for PET imaging of galectin-1 overexpressing bladder tumors.




bladder cancer

Harnessing Population Pedigree Data and Machine Learning Methods to Identify Patterns of Familial Bladder Cancer Risk

Background:

Relatives of patients with bladder cancer have been shown to be at increased risk for kidney, lung, thyroid, and cervical cancer after correcting for smoking-related behaviors that may concentrate in some families. We demonstrate a novel approach to simultaneously assess risks for multiple cancers to identify distinct multicancer configurations (multiple different cancer types that cluster in relatives) surrounding patients with familial bladder cancer.

Methods:

This study takes advantage of a unique population-level data resource, the Utah Population Database (UPDB), containing vast genealogy and statewide cancer data. Familial risk is measured using standardized incidence risk (SIR) ratios that account for sex, age, birth cohort, and person-years of the pedigree members.

Results:

We identify 1,023 families with a significantly higher bladder cancer rate than population controls (familial bladder cancer). Familial SIRs are then calculated across 25 cancer types, and a weighted Gower distance with K-medoids clustering is used to identify familial multicancer configurations (FMC). We found five FMCs, each exhibiting a different pattern of cancer aggregation. Of the 25 cancer types studied, kidney and prostate cancers were most commonly enriched in the familial bladder cancer clusters. Laryngeal, lung, stomach, acute lymphocytic leukemia, Hodgkin disease, soft-tissue carcinoma, esophageal, breast, lung, uterine, thyroid, and melanoma cancers were the other cancer types with increased incidence in familial bladder cancer families.

Conclusions:

This study identified five familial bladder cancer FMCs showing unique risk patterns for cancers of other organs, suggesting phenotypic heterogeneity familial bladder cancer.

Impact:

FMC configurations could permit better definitions of cancer phenotypes (subtypes or multicancer) for gene discovery and environmental risk factor studies.




bladder cancer

Seattle Genetics, Astellas' bladder cancer med Padcev blows early expectations out of the water

Even a pandemic can’t slow down Seattle Genetics and Astellas' new bladder cancer treatment Padcev, which "blew out sales expectations" for the first quarter, analysts said. And now, they're jacking up their long-term sales estimates for the drug as a result.




bladder cancer

Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer




bladder cancer

UNC5B mediates G2/M phase arrest of bladder cancer cells by binding to CDC14A and P53